Showing 1 - 10 of 25
We develop a two-period model applicable to global sourcing by considering a firm that operates in two markets: one is located in the U.S. and the second is in a country having a selling season that does not overlap with the U.S. selling season. Demand for each market depends linearly on the...
Persistent link: https://www.econbiz.de/10009430665
We analyze the problem of determining inventory and pricing decisions in a two-period retail setting when an opportunity to refine information about uncertain demand is available. The model extends the newsvendor problem with pricing by allowing for multiple suppliers, the pooling of procurement...
Persistent link: https://www.econbiz.de/10009430684
We consider the problem of a newsvendor that is served by multiple suppliers, where any given supplier may be unreliable. By unreliable we simply mean that the marginal amount received from a supplier is no more than, and typically is less than, the marginal amount ordered from the supplier. In...
Persistent link: https://www.econbiz.de/10005553595
Persistent link: https://www.econbiz.de/10001945194
This dissertation involves three essays, studying firms' decision-making on marketing mix variables. Specifically, the first essay (Chapter 2) studies the effects of distribution channels on firms' advertising content decision. In many markets, consumers may not have full information of product...
Persistent link: https://www.econbiz.de/10009477743
Persistent link: https://www.econbiz.de/10001699383
Persistent link: https://www.econbiz.de/10001686917
Overconfidence is one of the most consistent, powerful, and widespread cognitive biases affecting decision making in situations characterized by random outcomes. In this paper, we study the effects and implications of overconfidence in a competitive newsvendor setting. In this context,...
Persistent link: https://www.econbiz.de/10013232281
Problem Definition: In 1992, FDA instituted the accelerated approval pathway (AP) to allow promising drugs to enter the market based on limited evidence of efficacy, thereby permitting manufacturers to verify true clinical benefits through post-market studies. However, most post-market studies...
Persistent link: https://www.econbiz.de/10012860973
We seek to understand how and when government should (and should not) intervene to stimulate green product development when competing firms with asymmetric credibilities communicate their environmental performance through ecolabels. To that end, we develop a consumer-driven model of green...
Persistent link: https://www.econbiz.de/10014034837